300% Dividend: Pharma Giant Announces 299% YoY Growth In Net, Shares Hit 52-Week High

Zydus Lifesciences Ltd shares rallied 4.28% in trade today to settle at Rs 1051.90 per share after the pharmaceuticals company declared its results and recommended dividend today. The board of directors of company recommended a final dividend of Rs 3.00/- per equity share of Re 1/- each and fixed July 26, 2024 as the record date. Zydus Lifesciences shares gave return of 51% year-to-date and zoomed 103% in last 1-year. The large cap pharmaceuticals firm has a market capitalisation of Rs 1,05,845.75 crore. More details below:

Zydus Lifesciences Recommends Dividend: According to the BSE filing of Zydus Lifesciences dated May 17, 2024, "final dividend of Rs.3.00/- (@ 300%) per equity share of Re. 1/- each, subject to approval of the shareholders at the AGM."

Zydus Lifesciences Sets Record Date For Dividend: The exchange filing added, "the Record Date as Friday, July 26, 2024, in compliance with regulation 42(1) of the Listing Regulations, to determine the list of shareholders entitled to receive the final dividend for the Financial Year ended on March 31, 2024, payment of which shall be subject to the approval by the members at the AGM."

Zydus Q4: According to the BSE filing of the pharma major revenue from operations was Rs. 55,338 mn for March 2024 quarter, up 10% over last year. Research & Development (R&D) investments for the March 2024 quarter stood at Rs. 3,516 mn (6.4% of revenues). EBITDA for the quarter was Rs. 16,305 mn, up 30% YoY. EBITDA margin for the quarter stood at 29.5%, an improvement of 440 bps on a YoY basis. Net Profit for the March 2024 quarter was Rs. 11,823 mn, up 299% YoY. Capex (organic) for the quarter was Rs. 2,126 mn.

For the whole year, revenue from operations was Rs. 195,474 mn, up 13% over last year. EBITDA was Rs. 53,843 mn, up 40% YoY. EBITDA margin stood at 27.5%, an improvement of 510 bps over the previous year. Net Profit was Rs. 38,595 mn, up 97% YoY.

Zydus Lifesciences Share Performance: The 52-week high price of Zydus Lifesciences share on BSE is Rs 1057.00 per share (as on 17/05/2024) and 52-week low price is Rs 482.55 per share (as on 22/05/2023). Zydus Lifesciences shares offered return of 7% in last 1-weeks, gained 65% in last 1-year, soared 201% in last 2-years, and surged 321% in last 5-years.

Zydus Lifesciences About: Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. From formulations to active pharmaceutical ingredients and animal healthcare products to wellness products, Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions, according to its official website.

Disclaimer: The stock highlights the dividend, Q4 and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.